IDO rout: Piv­otal tri­als with Bris­tol-My­ers, Mer­ck and As­traZeneca dumped in wake of In­cyte's PhI­II im­plo­sion

The IDO R&D pipeline is in dan­ger of be­ing ex­ter­mi­nat­ed.

In the wake of a piv­otal fail­ure of In­cyte’s $IN­CY lead IDO drug epaca­do­stat, Bris­tol-My­ers Squibb $BMY be­came the third play­er forced to re­trench in that im­muno-on­col­o­gy field, drop­ping three late-stage stud­ies of a ri­val drug it bagged in a $1.25 bil­lion buy­out. But that was just the start of a rout.

In­cyte re­port­ed this morn­ing that its wide-rang­ing col­lab­o­ra­tions with Big Phar­ma play­ers are com­ing un­done. In their Q1 an­nounce­ment, echo­ing the fail­ure of ECHO-301, the com­pa­ny not­ed:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER